Author:
Vervandier J.,Caoduro C.,Boulahdour H.
Subject
Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology,Biophysics
Reference22 articles.
1. [123 I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease: [123 I]-FP/CIT SPECT in drug-induced Parkinsonism;Lorberboym;Mov Disord,2006
2. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group;Grosset;Mov Disord,2000
3. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes;Vlaar;Eur Neurol,2008
4. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62(2):133-40. doi:10.1136/jnnp.62.2.133. PMID: 9048712; PMCID: PMC486723.
5. Impact of dopamine transporter SPECT using123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes;Catafau;Mov Disord,2004